Full Breakdown
Iran Conflict Sends Shockwaves Through Global Pharmaceutical Supply Chains
4/25/2026, 1:50:13 AM
Disruption Overview
The war between Israel, the United States and Iran, and the ensuing blockade of the Strait of Hormuz, have sharply curtailed the flow of petroleum-derived feedstocks and air-freight routes that underpin the production and distribution of many medicines. One-in-five NHS medicines is imported by air; the conflict has doubled air-freight costs and raised global shipping rates, feeding higher wholesale prices for generic drugs.
Background & Context
Pharmaceutical manufacturing relies heavily on petrochemical derivatives sourced from the Persian Gulf. The same routes also support cold-chain logistics for vaccines and life-saving drugs. Lessons from the COVID-19 pandemic prompted some nations to stockpile essential therapeutics, yet the concentration of active-ingredient production in India and China leaves the sector vulnerable to Gulf disruptions.
Data & Statistics
- In England, over-the-counter paracetamol prices rose 20-30 % after February; wholesale cost jumped from 41 p to £1.99 per 100-tablet pack, later easing to £1.09.
- Cetirizine purchase price nearly doubled from 19 p to 37 p per 30-tablet pack.
- The National Pharmacy Association reports a 40-50 % increase in pharmacy ordering costs and a 700 % rise in transportation expenses for manufacturers.
- The UK price-concessions list grew to 230 items in March, up from 90 the previous year.
- Switzerland’s Federal Office for National Economic Supply flagged 140 essential pharmaceuticals as “limited.”
- India saw a 96 % surge in paracetamol prices, while Al Jazeera notes a possible 30-40 % further rise.
Impact on National Pharmacies
UK community pharmacies, which derive 90 % of revenue from NHS prescriptions, are reimbursed at fixed rates; the surge in wholesale costs forces many to sell at a loss. In England, a 32-tablet pack of paracetamol now costs consumers £1.50, up from £1.19 pre-conflict. Indian chemists report similar spikes, and Sudan’s Qoz Nafisa clinic, serving 5 000 people, has run out of malaria treatment and faces delayed shipments worth $130 000. Swiss generic painkillers remain vulnerable, with supply chains strained by higher shipping costs and limited domestic production.
Official Statements & Responses
Olivier Picard, chair of the NPA, said pharmacies are paying 40-50 % more to order stock and warned that “the cost of medicine is soaring and ends up being pharmacies dispensing at a loss.” Mark Samuels, chief executive of Medicines UK, noted that “transportation costs have risen by 700 % and some chemicals needed for manufacturing are in very short supply.” Swiss authorities, through FONES, have marked essential therapeutic goods as limited and are amending the epidemics law to grant the government greater intervention powers. The UK government can raise reimbursement for items on the price-concessions list, a mechanism now covering 230 medicines.
Criticism & Opposition
Swiss pharmacist Enea Martinelli criticized the “too slow” political response to supply-chain shocks, while UK pharmacists urged against panic buying, warning it would exacerbate shortages. NGOs in Sudan argue that limited stockpiles and delayed aid shipments leave vulnerable populations without essential treatments.
On-the-Ground Reports
At the Qoz Nafisa clinic, patients queue for glaucoma medication while staff report no malaria drugs for days. In England, pharmacists recount customers confronting empty shelves for aspirin and paracetamol, prompting some outlets to suspend over-the-counter sales of certain strengths.
Conflicting Reports & Gaps
The Guardian cites a 20-30 % price rise for UK paracetamol, whereas Al Jazeera reports a quadrupling of the same drug’s price in the same market. Indian price increases are reported as 96 % by a former Visakha Chemists board member, while other analysts project a further 30-40 % rise. Data on actual stock levels in many low-income countries remain scarce.
Verbatim Quotes
- “It means that the cost of medicine is soaring and ends up being pharmacies dispensing at a loss,” — Olivier Picard, Chair, National Pharmacy Association
- “Mark Samuels, chief executive of Medicines UK, which represents the manufacturers supplying 85% of NHS prescriptions, said: “While the Iran conflict has not yet led to immediate or widespread medicine shortages for the NHS, this is due to stock already held in UK warehouses.” — Mark Samuels, CEO, Medicines UK
- “Pharmaceuticals are tied to both petrochemical feedstocks, a large part of which are sourced through the Persian Gulf,” — Frederic Schneider, Nonresident Senior Fellow, Middle East Council on Global Affairs
- “35 percent of pharmaceuticals move by air, and about 90 percent of critical or life-saving pharmaceuticals and vaccines do so too.” — Wouter Dewulf, Professor, University of Antwerp
- “The situation changes very fast for our system to be able to cope with it, and our political system is just too slow,” — Enea Martinelli, Swiss pharmacist, citizen-initiative committee
- “There’s still a real lag in the system. Shipments remain blocked or delayed, and that’s deeply worrying,” — Madiha Raza, Associate Director, International Rescue Committee
What’s Next
The UK is expected to expand the price-concessions list as more items exceed cost thresholds, while Switzerland plans to simplify EU imports, introduce QR-coded medicine leaflets, and classify drugs by usage to improve monitoring. Continued closure of the Strait of Hormuz could trigger further price hikes and force additional stock-piling measures across affected health systems.
